#CancerTreatment Archives

Combination Therapy for Advanced Gastric and Esophageal Cancers: Results from the OASIS Trial

By Mourabit Halima 2024.12.02

Editor's note : Recently, Nature Communications (IF=14.7) published an article entitled "Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial" by…

Dr. Feng Wang: Current Status and Challenges of Hepatocellular Carcinoma (HCC) Conversion Therapy in the Era of Integrated Medicine

By Lisa Cui 2024.10.08

Liver cancer is one of the most common malignant tumors in China, ranking second in cancer-related deaths. This highlights the significant burden of liver cancer prevention and treatment in the…

EAU24 Interview丨Dr. Junlong Zhuang and Dr. Bertrand Tombal jointly interpret the ARASENS study and explore intensive treatment strategies for mHSPC

By Mourabit Halima 2024.04.29

Editor's note: In recent years, on the basis of androgen deprivation therapy (ADT), new endocrine therapies such as AR pathway inhibitors have become standard treatments for patients with metastatic hormone-sensitive…

Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China

By Mourabit Halima 2024.03.20

Introduction: Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a pivotal therapeutic modality for lymphoma and multiple myeloma (MM), offering promising outcomes in improving patient prognosis. In China, the…

Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China

By Mourabit Halima 2024.03.18

Anlotinib: A Promising Therapeutic Approach for Transformed Follicular Lymphoma

By Mourabit Halima 2024.03.18

Introduction: Transformed follicular lymphoma (tFL) presents a formidable challenge in clinical oncology due to its high tumor mutational burden and therapeutic resistance. While anlotinib has demonstrated efficacy in solid tumors,…

Intensified Conditioning Regimens for High-Risk ALL Patients Undergoing Allo-HSCT: A Retrospective Analysis

By Mourabit Halima 2024.03.15

Editor's note: The prognosis of high-risk acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains variable, particularly concerning minimal residual disease (MRD) status. Professor Yu Hu…

WCLC Interview | Dr. Clarissa Baldotto: Treatment strategies after failure of immunotherapy for lung cancer

By Mourabit Halima 2024.02.13

The 2023 World Conference of Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was grandly held in Singapore from September 9th to 12th. At the WCLC conference, Dr. Clarissa Baldotto, President of the Brazilian Group of Thoracic Oncology, was invited by “Oncology frontier” to talk about the treatment strategies for lung cancer after immunotherapy failure, as well as the current status and future development of oncology in Brazil.

ESMO in Five Minutes | Prof. Haitao Zhao : Highlights of Advances in the Treatment of Cholangiocarcinoma

By Mourabit Halima 2024.01.19

95MO: Efficacy of Tinengotinib in Treating Advanced Fibroblast Growth Factor Receptor (FGFR) Inhibitor Resistant/Recurrent Cholangiocarcinoma Patients Background Fibroblast Growth Factor Receptor inhibitors (FGFRi) have been shown to play a role…

Efficacy & safety of Mitoxantrone Liposome in treating peripheral T-cell lymphomas: A real-world study (MOMENT)

By Lisa Cui 2024.01.18

Efficacy and safety of mitoxantrone hydrochloride liposome injection in treatment of peripheral T-cell lymphomas: a multicenter, non-interventional, ambispective cohort, real-world study (MOMENT) In August 2023, Professor Jun Ma and his…